Pharmacia & Upjohn and Centocor Partner to Promote FRAGMIN in the US

Strategic Insights -

Pharmacia & Upjohn, a global pharmaceutical and healthcare company, and Centocor, a leading biopharmaceutical company, have announced an agreement to co-promote FRAGMIN (dalteparin sodium injection) in the United States. The agreement aims to strengthen Pharmacia & Upjohn's FRAGMIN business in the US and enhance Centocor's leadership position in the acute cardiovascular marketplace. Under the agreement, Centocor will promote FRAGMIN to cardiovascular specialists after marketing clearance by the FDA for a new indication in the treatment of unstable angina. FRAGMIN is a low molecular weight heparin preparation marketed by Pharmacia & Upjohn in over 40 countries and is currently approved for the prevention of deep-vein thrombosis in patients at risk undergoing abdominal surgery in the US.

Key Takeaways:

  • Pharmacia & Upjohn and Centocor have agreed to co-promote FRAGMIN (dalteparin sodium injection) in the United States, targeting cardiovascular specialists.
  • The partnership aims to strengthen Pharmacia & Upjohn's FRAGMIN business in the US and enhance Centocor's leadership position in the acute cardiovascular marketplace.
  • Centocor will promote FRAGMIN after marketing clearance by the FDA for a new indication in the treatment of unstable angina.
  • FRAGMIN is a low molecular weight heparin preparation marketed by Pharmacia & Upjohn in over 40 countries.
  • The product is currently approved for the prevention of deep-vein thrombosis in patients at risk undergoing abdominal surgery in the US.

Statistics:

  • FRAGMIN is marketed by Pharmacia & Upjohn in over 40 countries.
  • Centocor's ReoPro and RETAVASE hold more than 50 percent of the acute coronary syndrome market.
  • FRAGMIN would be the third product in Centocor's cardiovascular portfolio, joining ReoPro and RETAVASE.

Sources:

  • PRNewswire
  • Pharmacia & Upjohn
  • Centocor, Inc. (Nasdaq: CNTO)